Although we elected to fully interrogate the activity of panobinostat, the other FDA-approved pan-HDAC inhibitors, including vorinostat or belinostat, with biologic activity like panobinostat, would be as attractive for further evaluating as monotherapy against AML expressing NPM1c. Here, HDAC9 is linked to acute myeloid leukemia.